Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
SRPT
SRPT
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
SRPT News
SAREPTA THERAPEUTICS, INC.: DEUTSCHE BANK INCREASES TARGET PRICE FROM $12 TO $14
4d ago
moomoo
SAREPTA THERAPEUTICS INC: WEDBUSH INCREASES TARGET PRICE FROM $29 TO $35
4d ago
moomoo
SAREPTA THERAPEUTICS INC: CITIGROUP INCREASES TARGET PRICE FROM $9 TO $13
4d ago
moomoo
SAREPTA THERAPEUTICS INC: PIPER SANDLER INCREASES TARGET PRICE FROM $16 TO $23
4d ago
moomoo
Sarepta's Promising Data Sparks Market Optimism
5d ago
stocktwits
SRPT Stock Sees Largest Daily Increase in Almost 8 Years Following Rare Muscle Disorders Study, Yet Wall Street Remains Skeptical
5d ago
stocktwits
Sarepta Reports Promising Clinical Results for siRNA Programs
5d ago
NASDAQ.COM
Precious Metals Stocks Surge, Led by Aura Minerals
5d ago
NASDAQ.COM
Sarepta Shares Jump 30% Following Gene Therapy Trials, But Safety Concerns Persist.
5d ago
Barron's
Sarepta Shares Jump 29% Following Gene Therapy Trials, But Safety Concerns Persist.
5d ago
Barron's
Sarepta Therapeutics Shares Surge 25% on Promising Clinical Trial Data
5d ago
seekingalpha
Sarepta Reports Promising Results in Genetic Muscle Disease Trials
5d ago
stocktwits
SRPT Shares Surge Following Positive Initial Results for RNA Treatments Aimed at Rare Muscle Disorders
5d ago
stocktwits
Sarepta Therapeutics Stock Rises 3.2% in Premarket Trading Following Positive Early-to-Mid Stage Trial Results for Muscle Disease Treatments
5d ago
moomoo
SAREPTA THERAPEUTICS INC - MOST ADVERSE EVENTS IN STUDIES WERE MILD TO MODERATE AND NOT LINKED TO DOSAGE
5d ago
moomoo
SAREPTA THERAPEUTICS INC - EVIDENCE FROM PROOF-OF-CONCEPT STUDY INDICATES THAT A SINGLE DOSE OF SRP-1001 AND SRP-1003 LOWER TARGET PROTEIN OR MRNA LEVELS
5d ago
moomoo
Show More News
